News

FDA commissioner stirs debate over hormone therapy for menopause
A Food and Drug Administration (FDA) expert panel has reignited a debate over whether hormone therapy should be used to treat ...
BioPharma Dive4h
FDA delays approval decision for Bayer menopause therapy
The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...
Healio8d
FDA panel calls for label changes, more education on menopausal hormone therapy
Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...
Managed Healthcare Executive8d
FDA Panel Challenges Hormone Replacement Therapy Risks
A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...
The FDA May Finally Remove The Black Box Warning On Hormone Therapy Products. Here’s When It Might Happen
The FDA is reconsidering the black box warning on estrogen. Experts say it’s time for a change—find out what this means for ...
BizPac Review3d
‘All of us are begging’: New push for FDA to remove ‘black box’ warnings from menopause products
The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...
Science News7d
U.S. FDA may nix black box warning on some menopause estrogen treatments
Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.
How one controversial study shaped 20 years of menopause care
Hone Health reports that the controversial 2002 WHI study misled menopause care, linking HRT to breast cancer and causing ...
Fierce Pharma14d
Bayer scores first approval for hormone-free menopause drug Lynkuet in UK
While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...
The Manila Times4d
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary ...
Daré Bioscience, Inc.: Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive
Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today ...